• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Pancreatic neoplasm histology predicts survival

bys25qthea
July 25, 2013
in Chronic Disease, Endocrinology, Gastroenterology, Oncology
Reading Time: 3 mins read
Pancreatic islet autotransplantation a potential treatment for malignant disease
Share on FacebookShare on Twitter

Image: PD

1. Pathohistological subtype of pancreatic intraductal papillary mucinous neoplasm (IPMN) was a strong independent predictor for malignancy. 

2. Pancreatobiliary type IPMN was associated with poor prognosis as well as malignant behavior and high recurrence potential. Survival rates were similar to pancreatic ductal adenocarcinoma, a cancer with similar tumor biology, suggesting that adjuvant therapy should be considered for patients diagnosed with pancreatobilary subtype.

Evidence Rating Level: 1 (Excellent)       

Study Rundown: IPMN histology is subdivided into intestinal, pancreatobiliary, gastric and oncologic types which differ by mucin expression. This study examined the relationship between each IPMN subtype, cancer recurrence and patient survival. Individual pathohistologic subtype was a strong independent prognosticator of survival. This study was limited by its restriction to only two cancer referral centers and the low number of cases in each subtype. Given the low incidence of this disease however, the sample size achieved in this study is robust and authors were able to show significant association with survival and recurrence rates. While there was appropriately long individual patient follow up, the entire study spanned 15 years during which time improvement of surgical technique and quality of care may have affected survival results.

Click to read the study in Annals of Surgery

RELATED REPORTS

Daraxonrasib extends survival in metastatic pancreatic cancer

2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

2 Minute Medicine Rewind July 13, 2026

Relevant Reading: Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas: Its Histopathologic Difference Between 2 Major Types

In-Depth [retrospective cohort study]: This study identified 103 cases of IPMN at two medical institutions from 1995 to 2010 with a mean follow-up of 59 months. Post-resection specimens were examined for pathohistologic subtype and duct involvement. The subtypes were divided as follows: 44% intestinal, 40% pancreatobiliary, 4% oncocytic and 12% gastric. No significant difference in CEA or CA 19-9 levels was detected between the subtypes. Pancreatobiliary and intestinal-type tumors were highly associated and moderately associated with invasive carcinoma respectively, while gastric IPMNs had a lower rate of malignancy conversion. Of the malignant subtypes, pancreatobiliary tumors were most likely to recur (p<0.001). Pancreatobiliary IPMN tumors were also associated with the poorest prognosis, demonstrating a 35.6% chance of 5-year survival, compared to 86.6% in the intestinal subtype, which represented the best prognosis. Invasive pancreatobiliary neoplasms were associated with an even lower 5-year survival of 28.1%(mean 38 mo. p<0.001)and were found to be similar to matched patients with pancreatic ductal adenocarcinoma.

By Asya Ofshteyn and Chaz Carrier

More from this author: Pancreatic islet autotransplantation a potential treatment for malignant disease, Antibiotic implants reduce surgical site infections, Validated index scores severity of postsurgical morbidity, Neoadjunctive radiotherapy, hospital factors key for rectal cancer resection, Laparoscopic splenectomy yields better outcomes than open

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: adjuvant therapyIPMNpancreatic cancerpathology
Previous Post

The CHEST-1 & PATENT-1: Riociguat significantly improves exercise capacity in pulmonary hypertension patients

Next Post

Scleral buckle is more cost effective than vitrectomy for phakic patients

RelatedReports

Oncology

Daraxonrasib extends survival in metastatic pancreatic cancer

September 17, 2026
Pharma Roundup

2MM: Pharma Roundup – mRNA flu vaccine debuts, RAS inhibition extends pancreatic cancer survival, and new therapies advance for dermatomyositis and Tourette syndrome

September 15, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Weekly Rewinds

2 Minute Medicine Rewind July 13, 2026

July 13, 2026
Oncology

New targeted therapy daraxonrasib improves survival in pancreatic cancer

May 5, 2026
Next Post

Scleral buckle is more cost effective than vitrectomy for phakic patients

New genetic link in pulmonary arterial hypertension holds therapeutic promise

New genetic link in pulmonary arterial hypertension holds therapeutic promise

Safer in the big city: Injury-related deaths more common in rural areas

Safer in the big city: Injury-related deaths more common in rural areas

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Nirsevimab (Beyfortus) may reduce severe respiratory syncytial virus infections among infants
  • An artificial intelligence (AI) tool achieved high diagnostic accuracy for the identification and prediction of sepsis
  • Use of long-acting broadly neutralizing antibodies may delay human immunodeficiency virus (HIV) rebound following discontinuation of antiretroviral therapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.